[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Pescatori M, Stubbs AP, van Ijcken WF, Dahlke MH, Eggenhofer E, Weimar W, Hoogduijn MJ: Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol; 2010 Dec;162(3):474-86
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells.
  • There is emerging interest in the application of mesenchymal stem cells (MSC) for the prevention and treatment of autoimmune diseases, graft-versus-host disease and allograft rejection.
  • Adipose tissue-derived mesenchymal stem cells (ASC) were cultured with alloactivated peripheral blood mononuclear cells (PBMC) (mixed lymphocyte reaction: MLR), with proinflammatory cytokines [interferon (IFN)-γ, tumour necrosis factor (TNF)-α and interleukin (IL)-6] or under control conditions, and their full genome expression and function examined.
  • Therefore, in vitro preconditioning provides ASC with improved properties for immediate clinical immune therapy.
  • [MeSH-major] Cyclooxygenase 2 / biosynthesis. Cytokines / pharmacology. Indoleamine-Pyrrole 2,3,-Dioxygenase / metabolism. Inflammation Mediators / pharmacology. Mesenchymal Stromal Cells / drug effects
  • [MeSH-minor] Adipose Tissue / cytology. Cell Proliferation. Cells, Cultured. Coculture Techniques. Gene Expression Profiling. Gene Expression Regulation / immunology. Humans. Immunosuppression. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / metabolism. Lymphocyte Activation

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.
  • [Cites] Blood. 2002 May 15;99(10):3838-43 [11986244.001]
  • [Cites] Stem Cells. 2007 Jul;25(7):1753-60 [17395776.001]
  • [Cites] Bioinformatics. 2003 Feb 12;19(3):368-75 [12584122.001]
  • [Cites] Blood. 2003 May 1;101(9):3722-9 [12506037.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Apr;36(4):568-84 [15010324.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4619-21 [15001472.001]
  • [Cites] Science. 1999 Apr 2;284(5411):143-7 [10102814.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1815-22 [15494428.001]
  • [Cites] Eur J Immunol. 2005 May;35(5):1482-90 [15827960.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23(6):727-37 [15917469.001]
  • [Cites] Clin Exp Immunol. 2007 Aug;149(2):353-63 [17521318.001]
  • [Cites] Lab Invest. 2007 Sep;87(9):858-70 [17607298.001]
  • [Cites] Stem Cells Dev. 2007 Aug;16(4):597-604 [17784833.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3691-4 [17684157.001]
  • [Cites] Stem Cells. 2008 Jan;26(1):212-22 [17932417.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2008 Jan-Feb;56(1):1-8 [18250975.001]
  • [Cites] Cell Stem Cell. 2008 Feb 7;2(2):141-50 [18371435.001]
  • [Cites] Eur J Immunol. 2008 Jun;38(6):1745-55 [18493986.001]
  • [Cites] Transl Res. 2008 Jun;151(6):293-302 [18514140.001]
  • [Cites] Transpl Immunol. 2008 Nov;20(1-2):55-60 [18762258.001]
  • [Cites] Am J Transplant. 2009 Jan;9(1):222-30 [18976299.001]
  • [Cites] Transpl Int. 2009 Apr;22(4):365-76 [19000235.001]
  • [Cites] Transplantation. 2009 Mar 27;87(6):896-906 [19300194.001]
  • [Cites] Cytotherapy. 2009;11(5):570-83 [19565371.001]
  • [Cites] Transplantation. 2009 Sep 15;88(5):614-9 [19741455.001]
  • [Cites] Tissue Eng Part A. 2009 Oct;15(10):2795-806 [19231921.001]
  • [Cites] Eur J Immunol. 2009 Dec;39(12):3436-46 [19798683.001]
  • [Cites] J Immunol. 2010 Mar 1;184(5):2321-8 [20130212.001]
  • [Cites] Stem Cells Dev. 2010 May;19(5):693-706 [20067407.001]
  • [Cites] Stem Cells. 2006 Feb;24(2):386-98 [16123384.001]
  • [Cites] J Immunol. 2006 Aug 15;177(4):2080-7 [16887966.001]
  • [Cites] Cytotherapy. 2006;8(4):315-7 [16923606.001]
  • [Cites] J Cell Biochem. 2006 Aug 1;98(5):1076-84 [16619257.001]
  • [Cites] Eur J Immunol. 2006 Oct;36(10):2566-73 [17013987.001]
  • [Cites] Mol Biol Cell. 2002 Dec;13(12):4279-95 [12475952.001]
  • (PMID = 20846162.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE18662
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 0 / Inflammation Mediators; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC3026550
  •  go-up   go-down


2. Luetzkendorf J, Mueller LP, Mueller T, Caysa H, Nerger K, Schmoll HJ: Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J Cell Mol Med; 2010 Sep;14(9):2292-304
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence.
  • Colorectal carcinoma (CRC) constitutes a common malignancy with limited therapeutic options in metastasized stages.
  • Mesenchymal stem cells (MSC) home to tumours and may therefore serve as a novel therapeutic tool for intratumoral delivery of antineoplastic factors.
  • Tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) which promises apoptosis induction preferentially in tumour cells represents such a factor.
  • We generated TRAIL-MSC by transduction of human MSC with a third generation lentiviral vector system and analysed their characteristics and capacity to inhibit CRC growth. (1) TRAIL-MSC showed stable transgene expression with neither changes in the defining MSC characteristics nor signs of malignant transformation. (2) Upon direct in vitro coculture TRAIL-MSC induced apoptosis in TRAIL-sensitive CRC-cell lines (DLD-1 and HCT-15) but also in CRC-cell lines resistant to soluble TRAIL (HCT-8 and SW480). (3) In mixed subcutaneous (s.c.) xenografts TRAIL-MSC inhibited CRC-tumour growth presumably by apoptosis induction but a substantial proportion of TRAIL-MSC within the total tumour cell number was needed to yield such anti-tumour effect. (4) Systemic application of TRAIL-MSC had no effect on the growth of s.c.
  • DLD-1 xenografts which appeared to be due to a pulmonary entrapment and low rate of tumour integration of TRAIL-MSC.
  • Systemic TRAIL-MSC caused no toxicity in this model. (5) Wild-type MSC seemed to exert a tumour growth-supporting effect in mixed s.c.
  • These novel results support the idea that lentiviral TRAIL-transgenic human MSC may serve as vehicles for clinical tumour therapy but also highlight the need for further investigations to improve tumour integration of transgenic MSC and to clarify a potential tumour-supporting effect by MSC.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Lentivirus / genetics. Mesenchymal Stromal Cells / metabolism. TNF-Related Apoptosis-Inducing Ligand / genetics. TNF-Related Apoptosis-Inducing Ligand / therapeutic use. Transgenes / genetics
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Cell Membrane / metabolism. Cell Proliferation. Cell Transformation, Neoplastic / pathology. Drug Resistance, Neoplasm. Humans. Mesenchymal Stem Cell Transplantation. Mice. Mice, Nude. Solubility. Transduction, Genetic. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
  • (PMID = 19508388.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TNF-Related Apoptosis-Inducing Ligand
  • [Other-IDs] NLM/ PMC3822570
  •  go-up   go-down


3. De Padua M, Bhandari TP, Pingle J: Primary osteoliposarcoma of the bone. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):80-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some of the reports have referred to these tumors as malignant mesenchymoma.
  • Radiologically, a tumor in the lower end of the right femur was seen extending into the soft tissue.
  • The patient received three cycles of neo-adjuvant chemotherapy followed by limb-salvage surgery with provisions for a custom-made prosthesis.
  • Only 21% tumor necrosis (effects of chemotherapy) was observed.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biopsy. Femur / pathology. Femur / radiography. Humans. Male

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136790.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Goetz CM, Schmid I, Pietsch T, Peraud A, Haas RJ: Mixed malignant germ cell tumour of the lateral ventricle in an 8-month-old girl: case report and review of the literature. Childs Nerv Syst; 2002 Nov;18(11):644-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed malignant germ cell tumour of the lateral ventricle in an 8-month-old girl: case report and review of the literature.
  • CASE REPORT: We report a huge intracerebral malignant germ cell tumour (GCT) which appeared in the lateral ventricles of an 8-month-old girl.
  • Due to extensive tumour vascularisation only partial resection was achieved.
  • Histology revealed an embryonal carcinoma mixed with a teratoma.
  • Chemotherapy induced a marked regression of the tumour.
  • After chemotherapy complete resection of the tumour remnant was easily achieved.
  • Histology showed only mesenchymal differentiated tumour tissue and the embryonal carcinoma could no longer be detected.
  • More than 2 years after the second operation and 31 months after diagnosis the child remains tumour-free.
  • CONCLUSION: The majority of cranial mixed malignant GCTs affects patients older than 4 years of age.
  • [MeSH-major] Brain Neoplasms / therapy. Lateral Ventricles / pathology. Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Infant. Magnetic Resonance Imaging. Neoplasm, Residual. Reoperation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12420127.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


5. Bajpai M, Pal K, Agarwala S, Seth T, Gupta AK: Midterm results with hepatectomy after preoperative chemotherapy in hepatoblastoma. Pediatr Surg Int; 2005 May;21(5):364-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Midterm results with hepatectomy after preoperative chemotherapy in hepatoblastoma.
  • We evaluated the results of surgical treatment for hepatoblastoma in infants and children after intensive preoperative chemotherapy, with special reference to histology and extent of liver involvement.
  • The clinical features of 10 children with hepatoblastoma were reviewed regarding response to neoadjuvant chemotherapy, histological subtypes, extent of hepatectomy, operative complications, and prognosis.
  • Response to chemotherapy was measured by volumetric assessment of tumour size by computed tomography scan.
  • Cisplatin and Adriamycin (PLADO regime) up to three cycles markedly reduced the tumour volume on computed tomography (mean regression rate 65.9%); alpha-foetoprotein (AFP) levels also decreased from an initial mean of 16,116.4 ng/ml to 2,050.9 ng/ml.
  • Histopathology of resected specimens revealed foetal histology in four patients, poorly differentiated (anaplastic) subtype in three, and mixed histology with mesenchymal components and osteoid formation in three.
  • Moreover, hepatic resection tended to be less invasive in patients whose tumours had been much reduced after preoperative chemotherapy.
  • Preoperative administration of cisplatin and Adriamycin reduces the tumour size significantly so that a safe radical hepatectomy can be performed.
  • It also allows early administration of postoperative chemotherapy.
  • Although overall good results were obtained with the current protocol, we also document our experience of unfavourable outcomes in patients with bilobar tumours (despite trisegmentectomy), patients with tumours showing poor response to neoadjuvant chemotherapy, and patients with anaplastic histology.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatectomy. Hepatoblastoma / drug therapy. Hepatoblastoma / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Doxorubicin / therapeutic use. Female. Humans. Infant. Male. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Presse Med. 1954 May 5;62(33):709-12 [13177441.001]
  • [Cites] J Pediatr Surg. 1991 Sep;26(9):1074-80; discussion 1080-1 [1658289.001]
  • [Cites] J Pediatr Surg. 2002 Feb;37(2):240-5 [11819207.001]
  • [Cites] Surgery. 1991 Oct;110(4):726-34; discussion 734-5 [1656538.001]
  • [Cites] Artif Organs. 1995 Aug;19(8):866-9 [8573011.001]
  • [Cites] Mil Med. 1993 Jan;158(1):51-5 [7679785.001]
  • [Cites] Eur J Cancer. 1994;30A(8):1050-1 [7654427.001]
  • [Cites] J Pediatr Surg. 1992 Mar;27(3):292-6; discussion 297 [1323649.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1082-95 [2547506.001]
  • [Cites] J Pediatr Surg. 1984 Oct;19(5):523-6 [6094781.001]
  • [Cites] Surgery. 1991 Oct;110(4):591-6; discussion 596-7 [1656537.001]
  • [Cites] Curr Opin Pediatr. 1993 Feb;5(1):110-6 [8397039.001]
  • [Cites] J Clin Oncol. 1991 Dec;9(12):2167-76 [1720452.001]
  • [Cites] AJR Am J Roentgenol. 1993 Apr;160(4):793-8 [8384403.001]
  • [Cites] Surgery. 1998 Apr;123(4):407-14 [9551066.001]
  • [Cites] Ann Surg. 1991 Feb;213(2):118-21 [1847033.001]
  • [Cites] J Pediatr Surg. 1989 Nov;24(11):1167-8 [2553910.001]
  • [Cites] J Pediatr. 2000 Jun;136(6):795-804 [10839879.001]
  • [Cites] J Pediatr Surg. 1975 Jun;10 (3):329-37 [49416.001]
  • [Cites] J Pediatr Surg. 1989 Jan;24(1):24-8; discussion 29 [2542511.001]
  • [Cites] Semin Surg Oncol. 1993 Nov-Dec;9(6):532-40 [8284573.001]
  • [Cites] Med Pediatr Oncol. 1990;18(3):181-4 [1691816.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1080-3; discussion 1083-4 [1328586.001]
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):303-7; discussion 308 [10693685.001]
  • [Cites] Am J Surg Pathol. 1982 Dec;6(8):693-705 [6301295.001]
  • [Cites] J Pediatr Surg. 1995 Jun;30(6):845-52 [7545228.001]
  • [Cites] J Pediatr Surg. 1997 Jan;32(1):75-9 [9021575.001]
  • (PMID = 15838617.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; AP protocol 1
  •  go-up   go-down


6. Mrad K, Sassi S, Smida M, Oubiche F, Mekni A, Romdhane KB: Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. Pathologica; 2004 Dec;96(6):475-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone.
  • BACKGROUND: Primary malignant mesenchymoma of the bone is a rare neoplasm consisting of two or more unrelated malignant mesenchymal components.
  • OBSERVATION: We report an exceedingly rare case of primary malignant mesenchymoma of bone composed of rhabdomyosarcoma, osteosarcoma, and a minor chondrosarcoma component, arising in the right proximal humerus of a 15-year-old girl.
  • The rhabdomyosarcomatous component was present in the initial biopsy and persisted in surgical specimen following chemotherapy.
  • CONCLUSION: Effect of chemotherapy is enigmatic since rhabdomyosarcomatous component could appear, persist or disappear after chemotherapy according to literature.
  • [MeSH-major] Bone Neoplasms / pathology. Humerus / pathology. Mesenchymoma / pathology. Neoplasms, Multiple Primary / pathology. Osteosarcoma / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adolescent. Antimetabolites, Antineoplastic / therapeutic use. Chondrosarcoma / diagnosis. Chondrosarcoma / drug therapy. Chondrosarcoma / pathology. Chondrosarcoma / radiography. Chondrosarcoma / surgery. Combined Modality Therapy. Desmin / analysis. Diagnosis, Differential. Fatal Outcome. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Fibrosarcoma / radiography. Fibrosarcoma / surgery. Humans. Methotrexate / therapeutic use. Neoplasm Proteins / analysis. Osteolysis / etiology. Postoperative Complications / etiology. Pulmonary Embolism / etiology. Sarcoma, Ewing / diagnosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for malignant mesenchymoma .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792374.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Desmin; 0 / Neoplasm Proteins; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 12
  •  go-up   go-down


7. Lee JA, Kim TW, Min JH, Byon SJ, Jang SH, Choi SY, Kim HJ: [A case of undifferentiated (embryonal) liver sarcoma mimicking klatskin tumor in an adult]. Korean J Gastroenterol; 2010 Feb;55(2):144-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of undifferentiated (embryonal) liver sarcoma mimicking klatskin tumor in an adult].
  • Undifferentiated sarcoma is an uncommon primary malignant tumor of the liver typically occurring in older children.
  • It is also referred to as malignant mesenchymoma, fibromyxosarcoma, or mesenchymal sarcoma.
  • The pathologic finding revealed infiltrative growth of atypical cells with rhabdoid features.
  • These tumor cells were positive for vimentin only, and the tumor was consistent with undifferentiated sarcoma of the liver.
  • [MeSH-minor] Aged. Bile Ducts, Intrahepatic / pathology. Diagnosis, Differential. Dilatation, Pathologic. Humans. Klatskin Tumor / diagnosis. Male. Positron-Emission Tomography. Tomography, X-Ray Computed. Tuberculosis / diagnostic imaging. Tuberculosis / drug therapy. Ultrasonography. Vimentin / metabolism

  • Genetic Alliance. consumer health - Embryonal Sarcoma.
  • Genetic Alliance. consumer health - Klatskin tumor.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168062.001).
  • [ISSN] 2233-6869
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Vimentin
  •  go-up   go-down


8. Deslée G, Guillou PJ, Baehrel B, Lebargy F: Malignant mesenchymoma of the pleura. Interact Cardiovasc Thorac Surg; 2003 Sep;2(3):376-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesenchymoma of the pleura.
  • Malignant mesenchymomas are rare soft tissue tumors of mesenchymal origin.
  • The treatment associated surgical resection, chemotherapy and radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670075.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Chow LT, Kumta SM: Primary osteochondrorhabdomyosarcoma (malignant mesenchymoma) of the fibula: a rare tumour in an unusual site -- case report and review of the literature. APMIS; 2004 Sep;112(9):617-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteochondrorhabdomyosarcoma (malignant mesenchymoma) of the fibula: a rare tumour in an unusual site -- case report and review of the literature.
  • Malignant mesenchymoma, defined by Stout as sarcomas comprising two or more unrelated differentiated tissue elements other than a fibrosarcoma component, is rare.
  • We report a case of primary malignant mesenchymoma of the proximal fibula in a 10-year-old female student who presented with pain and swelling of the right knee for 2 months.
  • Including our present patient, 16 cases of primary malignant mesenchymoma of bone are found in the English literature, affecting mainly adolescents and young adults, with a slight male predominance and predilection for the metaphysis of long bones, especially around the knee.
  • The clinical features of primary malignant mesenchymoma of bone thus resemble those of conventional osteosarcoma.
  • Moreover, our case illustrates that, with combination chemotherapy targeted for individual elements, the prognosis of this rare tumour might be much improved, as in osteosarcoma.
  • [MeSH-major] Bone Neoplasms / pathology. Fibula / pathology. Mesenchymoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15601312.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 22
  •  go-up   go-down


10. Drabko K, Choma M, Zaucha-Prazmo A, Wójcik B, Gorczyńska E, Kałwak K, Turkiewicz D, Słociak M, Ussowicz M, Dyla A, Chybicka A, Styczyński J, Debski R, Wysocki M, Goździk J, Ratajczak M, Kowalczyk JR: [Megachemotherapy and autologous hematopoietic stem cell transplantation in children with solid tumours excluding neuroblastoma--experience of Polish paediatric centres]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):785-92
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 25 children were treated for Ewing Sarcoma, 13 for rhabdomyosarcoma embryonale (RMS), 7 for germinal tumours, 6 for medulloblastoma, 4 for PNET, 4 for Wilm's tumours, 2 for glioblastoma and single patients with mesenchymoma, astrocytoma, ependymoma, angioblastoma, carcinoma ovarian and carcinoma embryonale glutei.
  • In 29 children MCH was introduced in first complete remission, in 14 the procedure was performed in second or subsequent remission and 24 patients did not achieve remission before megachemotherapy was started.
  • RESULTS: 30 children are alive (44%), 28 of them in complete remission of disease.
  • 23 out of 29 (79%) patients were transplanted in first complete remission and median observation time in that group is 29 months (range 2-74 months).
  • 39 patients relapsed at a median time 11 months after MCT and 37 of them subsequently died of disease at a median time of 16 months.
  • One toxic death was noted--it was a boy, transplanted with progressive disease.
  • It is a safe procedure especially when performed in remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Neoplasms / drug therapy. Neoplasms / surgery
  • [MeSH-minor] Academic Medical Centers. Adolescent. Antineoplastic Agents, Alkylating / administration & dosage. Bone Neoplasms / drug therapy. Bone Neoplasms / surgery. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Ependymoma / drug therapy. Ependymoma / surgery. Female. Glioblastoma / drug therapy. Glioblastoma / surgery. Glioma / drug therapy. Glioma / surgery. Humans. Infant. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / surgery. Meningioma / drug therapy. Meningioma / surgery. Neoplasm Staging. Oncology Service, Hospital. Poland. Remission Induction. Retrospective Studies. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317909.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating
  •  go-up   go-down


11. Kutsal A, Tansal S, Okutan H, Tuncer I: Primary malignant mesenchymoma of the heart. Eur J Cardiothorac Surg; 2002 Jan;21(1):124-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant mesenchymoma of the heart.
  • Primary malignant cardiac tumours are uncommon, and cardiac malignant mesenchymoma is extremely rare.
  • A case of primary malignant mesenchymoma in a 41-year-old woman arousing from the left atrial septum, obstructing the mitral orifice by passing through it into the left ventricle is described.
  • The tumour was fully resected, and adjuvant chemotherapy was applied, but the patient had died by tumour recurrence in 8 months.
  • [MeSH-major] Heart Neoplasms / surgery. Mesenchymoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11788281.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Kiesslich T, Alinger B, Wolkersdörfer GW, Ocker M, Neureiter D, Berr F: Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Int J Oncol; 2010 Jan;36(1):49-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition.
  • Activation of developmental pathways has been recognized as a key mechanism for tumourigenesis and, hence, might be a valuable target for otherwise difficult to treat tumour entities such as biliary tract cancer (BTC).
  • Therefore, we performed a comprehensive analysis of the Wnt signalling pathway in 9 BTC cell lines on cell blocks, xenograft tumours and on human tissue microarrays by real-time reverse transcription PCR and by immunochemistry.
  • Furthermore, the effects of pharmacological pathway inhibition were investigated.
  • As a result we found a significant positive correlation of Wnt pathway activation with cyclin D1 expression and the proliferation parameters Ki67, cell cycle distribution, and growth kinetics as well as the mesenchymal marker vimentin and an inverse correlation with E-cadherin in BTC cell lines in vitro and in vivo.
  • In human BTC samples loss of membranous beta-catenin, an indicator of active Wnt signalling, correlated with vimentin expression and advanced tumour stage or metastasis, whereas membranous localisation of beta-catenin was associated with the differentiation marker cytokeratin-8/18 and differentiated tumour morphology (ductal or mixed type BTC).
  • In summary, activation of the Wnt pathway is associated with high proliferation, dedifferentiation and a solid morphology in human biliary tract cancer cell lines both in vitro and in vivo, and in human BTC tissues.
  • Further investigation of the mechanism(s) of Wnt pathway activation and its inhibition may provide new molecular treatment strategies for biliary tract cancer.
  • [MeSH-major] Biliary Tract Neoplasms / drug therapy. Biliary Tract Neoplasms / pathology. Signal Transduction. Wnt Proteins / metabolism
  • [MeSH-minor] Animals. Cell Cycle. Cell Differentiation. Cell Line, Tumor. Cell Proliferation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Vitro Techniques. Mice. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19956832.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Wnt Proteins
  •  go-up   go-down






Advertisement